An accurate cellular assay to determine pathogenicity of coding and noncoding variants in Lynch syndrome genes
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2517801123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Iris E Glykofridis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dutch Cancer Society, Dutch Research Council.
Abstract (Originalsprache)
Lynch syndrome (LS) is a genetic predisposition to mainly colorectal and endometrial cancer due to heterozygous disruptive germline mutations in the DNA mismatch-repair (MMR) genes MSH2 , MSH6 , MLH1, or PMS2 . Beyond clearly pathogenic mutations, germline sequencing often reveals variants of uncertain significance (VUS), predominantly single base-pair alterations in coding or noncoding regions. These uncertain variants obstruct LS diagnosis, hampering personalized surveillance. To address this challenge, we developed a highly accurate functional assay that interrogates VUS pathogenicity in human cells. Building on a mouse-based cellular assay, we adapted oligonucleotide-directed mutation screening (ODMS) for human cells and introduced a refined approach named “coselection ODMS.” To ensure physiological expression, the variant is introduced into the endogenous MMR gene by replication-coupled gene editing. Coselection ODMS demonstrated 100% accuracy in classifying 50 benign and 86 pathogenic variants spanning coding and noncoding regions in all four MMR genes. Among 109 patient-derived VUS, 51 were identified as deleterious for MMR function. Importantly, coselection ODMS delivered 100% concordant results in a clinical diagnostic laboratory. With >93% sensitivity and >92% specificity, coselection ODMS provides a highly reliable functional assay in the diagnosis of enigmatic LS variants, enabling risk assessment and personalized surveillance or treatment for affected families.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
- Biostatistics Centre, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
- Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam 3015 GD, The Netherlands.
ORCID-Profile: Iris E Glykofridis, Marleen Dekker, Yvonne Tiersma, Cédric G van der Ham, Beaunelle de Bruijn, Salma Ebrahim, Esmee Kasteleijn, Tjakko J van Ham, Hein Te Riele
Förderung
- Dutch Cancer Society
- Dutch Research Council
Zitieren
APA
Glykofridis, I. E., Dekker, M., Stoepker, C., van Ravesteyn, T. W., Tiersma, Y., van der Ham, C. G., de Bruijn, B., Ebrahim, S., de Menezes, R. X., Kasteleijn, E., Verheijen, F., van Ham, T. J., & Te Riele, H. (2026). An accurate cellular assay to determine pathogenicity of coding and noncoding variants in Lynch syndrome genes. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2517801123
Vancouver
Glykofridis IE, Dekker M, Stoepker C, van Ravesteyn TW, Tiersma Y, van der Ham CG, et al. An accurate cellular assay to determine pathogenicity of coding and noncoding variants in Lynch syndrome genes. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2517801123
BibTeX
@article{Glykofridis2026,
author = {Glykofridis, Iris E and Dekker, Marleen and Stoepker, Chantal and van Ravesteyn, Thomas W and Tiersma, Yvonne and van der Ham, Cédric G and de Bruijn, Beaunelle and Ebrahim, Salma and de Menezes, Renée X and Kasteleijn, Esmee and Verheijen, Frans and van Ham, Tjakko J and Te Riele, Hein},
title = {An accurate cellular assay to determine pathogenicity of coding and noncoding variants in Lynch syndrome genes},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2517801123}
}
EUVIMED